|
|
| Accelerate Drug Development From Transfection To GMP | Accelerating progress from cell line development to the production of GMP drug substance for Phase 1 and Phase 2 clinical trials is essential for success. At the same time, the need to align activities with funding milestones or adhere to a stepwise investment strategy imposes cost constraints. Our accelerated mAb development program shortens development timelines for IgG1 and IgG4 monoclonal antibodies to nine months. Learn more here. |
|
|
|
|
We catch up with Dr. Konstantin Konstantinov, CTO at Ring Therapeutics, and Ryan Crisman, Ph.D., cofounder and CTO at Umoja Biopharma, to get their thoughts on the future of new anellovirus vectors and existing lentiviral vector technology for in vivo gene delivery, respectively. |
|
|
|
Is there anything new that has popped up in the last year or so that has really affected how sites operate? Industry experts talk about some of the new challenges facing clinical trial sites in 2024. |
|
|
|
To understand where our RNA therapeutics are today and to start singling out where the opportunities exist to craft the next generation of RNA therapeutics, Anna Rose Welch sat down with four RNA executives. |
|
|
|
|
|
|
|
|
|
|
Inside you will find more on: - Executive Outlook
- Supply Chain Challenges
- Tomorrow's Leadership Skills
- Real-World Data
View the digital edition. |
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|
| Connect With Life Science Leader: |
|
|
|
